MA v Lindsay Clancy - Hillary Griffiths - Mass State Police Toxicology

Main points from the testimony of Mass State Police Forensic Scientist Hillary Griffiths in the Lindsay Clancy trial: Hillary Griffiths' Professional Background • Role and Experience: Hillary Griffiths is a forensic scientist in the toxicology unit of the Massachusetts State Police Crime Laboratory, where she has worked for 21 years. She joined the toxicology unit in 2011 after previously working in the DNA unit and the Office of Alcohol Testing. • Unit Purpose: The toxicology unit tests biological specimens—primarily blood and urine—for drugs, alcohol, and poisons to assist in criminal and legal investigations. Laboratory Testing Methodology and Procedures • Batch Testing System: The lab operates on a monthly batch system where individual analysts are assigned specific testing tasks. A single case may undergo three to ten different tests conducted by different scientists. • Case Review: Once all testing is complete, a designated reporting analyst reviews all raw data, police reports, and evidence documentation to generate the final toxicology report. • Two-Tiered Testing Strategy: • Screening: Samples undergo initial screening, such as an ELISA color screen (which looks for eight drug classes and is highly sensitive but not specific) and a "general unknown screen" (which looks for hundreds of prescription, over-the-counter, and abuse drugs). • Confirmation: Any positive screening results are subjected to secondary confirmatory testing to verify the exact substance present. • Blood vs. Urine Testing: • Blood: Used to determine both the presence and the specific concentration (quantitation) of a drug. • Urine: Used only to report whether a drug is detected or not. Quantitative concentration values are not reported for urine because they are not medically meaningful and do not reflect past blood concentrations. • Analytical Techniques: The lab utilizes *Solid Phase Extraction* to isolate drugs from other biological materials (like lipids and blood cells). It then uses *Liquid Chromatography-Mass Spectrometry (LC-MSMS)* to separate, identify, and quantify the specific drugs. If the lab cannot quantify a crucial substance in-house, it may outsource the sample to an independent facility, such as NMS Labs. Specific Results for Defendant Lindsay Clancy (Lab No. 23-01723) The laboratory received four vials of blood, two vials of serum plasma (separated from blood by the hospital), and one vial of urine collected in connection with the January 24, 2023, incident. Benzodiazepine Findings (Analyzed by Griffiths): • Urine Confirmation: Detected the presence of **nordiazepam, oxazepam, temazepam, and lorazepam**. Griffiths noted that diazepam commonly breaks down (metabolizes) in the body into nordiazepam, oxazepam, and temazepam, meaning their presence could stem from a single diazepam ingestion or separate prescriptions. • Blood Quantitation: • Lorazepam: 61 ng/mL • Nordiazepam: 20 ng/mL • Diazepam: 8.8 ng/mL • Oxazepam: 4.8 ng/mL • Temazepam: 1.9 ng/mL • Quality Control: All equipment controls associated with these tests performed appropriately and followed lab procedures. General Unknown Screen Findings (Analyzed by Lisa Yelle): • Other Detected Substances: The "organic bases and neutrals" screen detected *mirtazapine, lamotrigine, quetiapine, quetiapine metabolite, trazodone, and trazodone metabolite* in the blood. • Undetected Substances: There was **no alcohol detected**. Additionally, screens for amphetamines, buprenorphine, cocaine, fentanyl, methamphetamines, opiates, cannabinoids, and "organic acids and neutrals" were all negative. Lindsay Clancy Trial Playlist:    • MA v Lindsay Clancy - Jury Selection Day 1